Glucagon-Like Peptide-1 Receptor Regulates Thromboxane-Induced Human Platelet Activation

Katherine N. Cahill; Taneem Amin; Olivier Boutaud; Richard Printz; Dawn C. Newcomb; Dinah Foer; David J. Hodson; Johannes Broichhagen; Joshua A. Beckman; Chang Yu; Hui Nian; Mona Mashayekhi; Heidi J. Silver; James M. Luther; Nancy J. Brown; R. Stokes Peebles; Kevin Niswender

doi:10.1016/j.jacbts.2022.04.004

Glucagon-Like Peptide-1 Receptor Regulates Thromboxane-Induced Human Platelet Activation

Katherine N. Cahill, Taneem Amin, Olivier Boutaud, Richard Printz, Dawn C. Newcomb, Dinah Foer, David J. Hodson, Johannes Broichhagen, Joshua A. Beckman, Chang Yu, Hui Nian, Mona Mashayekhi, Heidi J. Silver, James M. Luther, Nancy J. Brown, R. Stokes Peebles, Kevin Niswender

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Original language	English (US)
Pages (from-to)	713-715
Number of pages	3
Journal	JACC: Basic to Translational Science
Volume	7
Issue number	7
DOIs	https://doi.org/10.1016/j.jacbts.2022.04.004
State	Published - Jul 2022

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jacbts.2022.04.004

Cite this

Cahill, K. N., Amin, T., Boutaud, O., Printz, R., Newcomb, D. C., Foer, D., Hodson, D. J., Broichhagen, J., Beckman, J. A., Yu, C., Nian, H., Mashayekhi, M., Silver, H. J., Luther, J. M., Brown, N. J., Peebles, R. S., & Niswender, K. (2022). Glucagon-Like Peptide-1 Receptor Regulates Thromboxane-Induced Human Platelet Activation. JACC: Basic to Translational Science, 7(7), 713-715. https://doi.org/10.1016/j.jacbts.2022.04.004

Cahill, KN, Amin, T, Boutaud, O, Printz, R, Newcomb, DC, Foer, D, Hodson, DJ, Broichhagen, J, Beckman, JA, Yu, C, Nian, H, Mashayekhi, M, Silver, HJ, Luther, JM, Brown, NJ, Peebles, RS & Niswender, K 2022, 'Glucagon-Like Peptide-1 Receptor Regulates Thromboxane-Induced Human Platelet Activation', JACC: Basic to Translational Science, vol. 7, no. 7, pp. 713-715. https://doi.org/10.1016/j.jacbts.2022.04.004

@article{30daa78bf0694b67a3f79640a5dd3b6d,

title = "Glucagon-Like Peptide-1 Receptor Regulates Thromboxane-Induced Human Platelet Activation",

author = "Cahill, {Katherine N.} and Taneem Amin and Olivier Boutaud and Richard Printz and Newcomb, {Dawn C.} and Dinah Foer and Hodson, {David J.} and Johannes Broichhagen and Beckman, {Joshua A.} and Chang Yu and Hui Nian and Mona Mashayekhi and Silver, {Heidi J.} and Luther, {James M.} and Brown, {Nancy J.} and Peebles, {R. Stokes} and Kevin Niswender",

note = "Funding Information: This work was supported by grants from the American Heart Association (17SFRN33520017); the Department of Medicine, Vanderbilt University Medical Center; and the National Institutes of Health (U19AI095227 and UL1 TR002243). Novo Nordisk and Merck provided investigational products. Dr Hodson was supported by Medical Research Council (MR/N00275X/1 and MR/S025618/1) and Diabetes UK (17/0005681) project grants. This project has received funding from the European Research Council under the European Union{\textquoteright}s Horizon 2020 Research and Innovation Programme (Starting Grant 715884 to Dr Hodson). Drs Hodson and Broichhagen have a licensing deal with Celtarys Research for distribution of LUXendin. Dr Beckman is a site-principal investigator in a Novo Nordisk–sponsored clinical trial in peripheral arterial disease. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Funding Information: This work was supported by grants from the American Heart Association (17SFRN33520017); the Department of Medicine, Vanderbilt University Medical Center; and the National Institutes of Health (U19AI095227 and UL1 TR002243). Novo Nordisk and Merck provided investigational products. Dr Hodson was supported by Medical Research Council (MR/N00275X/1 and MR/S025618/1) and Diabetes UK (17/0005681) project grants. This project has received funding from the European Research Council under the European Union's Horizon 2020 Research and Innovation Programme (Starting Grant 715884 to Dr Hodson). Drs Hodson and Broichhagen have a licensing deal with Celtarys Research for distribution of LUXendin. Dr Beckman is a site-principal investigator in a Novo Nordisk–sponsored clinical trial in peripheral arterial disease. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.",

year = "2022",

month = jul,

doi = "10.1016/j.jacbts.2022.04.004",

language = "English (US)",

volume = "7",

pages = "713--715",

journal = "JACC: Basic to Translational Science",

issn = "2452-302X",

publisher = "Elsevier Inc.",

number = "7",

}

TY - JOUR

T1 - Glucagon-Like Peptide-1 Receptor Regulates Thromboxane-Induced Human Platelet Activation

AU - Cahill, Katherine N.

AU - Amin, Taneem

AU - Boutaud, Olivier

AU - Printz, Richard

AU - Newcomb, Dawn C.

AU - Foer, Dinah

AU - Hodson, David J.

AU - Broichhagen, Johannes

AU - Beckman, Joshua A.

AU - Yu, Chang

AU - Nian, Hui

AU - Mashayekhi, Mona

AU - Silver, Heidi J.

AU - Luther, James M.

AU - Brown, Nancy J.

AU - Peebles, R. Stokes

AU - Niswender, Kevin

N1 - Funding Information: This work was supported by grants from the American Heart Association (17SFRN33520017); the Department of Medicine, Vanderbilt University Medical Center; and the National Institutes of Health (U19AI095227 and UL1 TR002243). Novo Nordisk and Merck provided investigational products. Dr Hodson was supported by Medical Research Council (MR/N00275X/1 and MR/S025618/1) and Diabetes UK (17/0005681) project grants. This project has received funding from the European Research Council under the European Union’s Horizon 2020 Research and Innovation Programme (Starting Grant 715884 to Dr Hodson). Drs Hodson and Broichhagen have a licensing deal with Celtarys Research for distribution of LUXendin. Dr Beckman is a site-principal investigator in a Novo Nordisk–sponsored clinical trial in peripheral arterial disease. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Funding Information: This work was supported by grants from the American Heart Association (17SFRN33520017); the Department of Medicine, Vanderbilt University Medical Center; and the National Institutes of Health (U19AI095227 and UL1 TR002243). Novo Nordisk and Merck provided investigational products. Dr Hodson was supported by Medical Research Council (MR/N00275X/1 and MR/S025618/1) and Diabetes UK (17/0005681) project grants. This project has received funding from the European Research Council under the European Union's Horizon 2020 Research and Innovation Programme (Starting Grant 715884 to Dr Hodson). Drs Hodson and Broichhagen have a licensing deal with Celtarys Research for distribution of LUXendin. Dr Beckman is a site-principal investigator in a Novo Nordisk–sponsored clinical trial in peripheral arterial disease. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

PY - 2022/7

Y1 - 2022/7

UR - http://www.scopus.com/inward/record.url?scp=85134535716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85134535716&partnerID=8YFLogxK

U2 - 10.1016/j.jacbts.2022.04.004

DO - 10.1016/j.jacbts.2022.04.004

M3 - Article

C2 - 35958685

AN - SCOPUS:85134535716

SN - 2452-302X

VL - 7

SP - 713

EP - 715

JO - JACC: Basic to Translational Science

JF - JACC: Basic to Translational Science

IS - 7

ER -

Glucagon-Like Peptide-1 Receptor Regulates Thromboxane-Induced Human Platelet Activation

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this